Avistone Biotechnology Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.2 months). See all sponsors →
Open Avistone Biotechnology Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| KANNON NCT06015503 |
P2 | Active, not recruiting | NSCLC (Non-small Cell Lung Cancer) | 139 | 2025-03-06 (+10 mo) |
| KYLIN-2 NCT06574347 |
P2 | Recruiting | Non-Small-Cell Lung Cancer | 120 | 2026-10-31 |
| KANNON-5 NCT07336732 |
P2 | Recruiting | Non-Small-Cell Lung Cancer | 40 | 2026-11 |
| KYLIN-1 NCT06343064 |
P1/2 | Recruiting | Non-Small-Cell Lung Cancer | 156 | 2026-12-31 (+24 mo) |
| KYLIN-3 NCT06970782 |
P3 | Not yet recruiting | Non-Small-Cell Lung Cancer | 278 | 2027-12-31 |
| KANNON-2 NCT06281964 |
P3 | Enrolling by invitation | Non-Small-Cell Lung Cancer | 327 | 2028-06-30 (+29 mo) |
| ANS02 NCT07538804 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer | 294 | 2029-06-30 |